While there were outliers, Marston said a major chunk of the investments are concentrated in a few key hubs: Pennsylvania and ...

Through its Genentech subsidiary, the pharmaceutical company promises to further the Triangle’s bona fides as a GLP-1 hotspot.

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...

One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels. 10 stocks we like ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

Eli Lilly LLY-0.58%decrease; red down pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...

An Eli Lilly drug candidate designed to hit three metabolic targets led patients to lose an average of 28.7% of their body weight in a late-stage clinical trial, setting a new high mark in the ...

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee ...

Eli Lilly has unveiled a new weight loss drug that appears to be delivering the highest weight loss yet in clinical trials while at the same time reducing knee arthritis pain. Participants on ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug. By Gina Kolata Gina Kolata has ...